<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article" xml:lang="EN"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Diabetes Care</journal-id><journal-id journal-id-type="hwp">diacare</journal-id><journal-id journal-id-type="pmc">dcare</journal-id><journal-id journal-id-type="publisher-id">Diabetes Care</journal-id><journal-title>Diabetes Care</journal-title><issn pub-type="ppub">0149-5992</issn><issn pub-type="epub">1935-5548</issn><publisher><publisher-name>American Diabetes Association</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">19228872</article-id><article-id pub-id-type="pmc">2671099</article-id><article-id pub-id-type="publisher-id">1736</article-id><article-id pub-id-type="doi">10.2337/dc08-1736</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Research</subject><subj-group><subject>Clinical Care/Education/Nutrition/Psychosocial Research</subject></subj-group></subj-group></article-categories><title-group><article-title>Coenzyme Q<sub>10</sub> Improves Endothelial Dysfunction in Statin-Treated Type 2 Diabetic Patients</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Hamilton</surname><given-names>Sandra J.</given-names></name><degrees>PGDIPHEALSC</degrees><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name><surname>Chew</surname><given-names>Gerard T.</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name><surname>Watts</surname><given-names>Gerald F.</given-names></name><degrees>DSC</degrees><xref ref-type="aff" rid="aff1"/><xref ref-type="corresp" rid="cor1"/></contrib><aff id="aff1">School of Medicine and Pharmacology, Royal Perth Hospital Unit, University of Western Australia, Perth, Australia.</aff></contrib-group><author-notes><corresp id="cor1">Corresponding author: Gerald F. Watts, <email>gerald.watts@uwa.edu.au</email></corresp></author-notes><pub-date pub-type="ppub"><month>5</month><year>2009</year></pub-date><pub-date pub-type="epub"><day>19</day><month>2</month><year>2009</year></pub-date><volume>32</volume><issue>5</issue><fpage>810</fpage><lpage>812</lpage><history><date date-type="received"><day>22</day><month>9</month><year>2008</year></date><date date-type="accepted"><day>6</day><month>2</month><year>2009</year></date></history><copyright-statement>&#x000a9; 2009 by the American Diabetes Association.</copyright-statement><copyright-year>2009</copyright-year><license license-type="creative-commons"><p>Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. See <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc-nd/3.0/">http://creativecommons.org/licenses/by-nc-nd/3.0/</ext-link> for details.</p></license><self-uri xlink:title="pdf" xlink:type="simple" xlink:href="zdc00509000810.pdf"/><abstract><sec><title>OBJECTIVE</title><p>The vascular benefits of statins might be attenuated by inhibition of coenzyme Q<sub>10</sub> (CoQ<sub>10</sub>) synthesis. We investigated whether oral CoQ<sub>10</sub> supplementation improves endothelial dysfunction in statin-treated type 2 diabetic patients.</p></sec><sec><title>RESEARCH DESIGN AND METHODS</title><p>In a double-blind crossover study, 23 statin-treated type 2 diabetic patients with LDL cholesterol &#x0003c;2.5mmol/l and endothelial dysfunction (brachial artery flow-mediated dilatation [FMD] &#x0003c;5.5%) were randomized to oral CoQ<sub>10</sub> (200 mg/day) or placebo for 12 weeks. We measured brachial artery FMD and nitrate-mediated dilatation (NMD) by ultrasonography. Plasma F<sub>2</sub>-isoprostane and 24-h urinary 20-hydroxyeicosatetraenoic acid (HETE) levels were measured as systemic oxidative stress markers.</p></sec><sec><title>RESULTS</title><p>Compared with placebo, CoQ<sub>10</sub> supplementation increased brachial artery FMD by 1.0 &#x000b1; 0.5% (<italic>P</italic> = 0.04), but did not alter NMD (<italic>P</italic> = 0.66). CoQ<sub>10</sub> supplementation also did not alter plasma F<sub>2</sub>-isoprostane (<italic>P</italic> = 0.58) or urinary 20-HETE levels (<italic>P</italic> = 0.28).</p></sec><sec><title>CONCLUSIONS</title><p>CoQ<sub>10</sub> supplementation improved endothelial dysfunction in statin-treated type 2 diabetic patients, possibly by altering local vascular oxidative stress.</p></sec></abstract></article-meta></front><body><p>Endothelial dysfunction portends diabetic vasculopathy. Endothelial dysfunction reflects increased vascular oxidative stress, whereby uncoupling of endothelial nitric oxide synthase activity and mitochondrial oxidative phosphorylation impairs the bioavailability and action of nitric oxide (<xref ref-type="bibr" rid="B1">1</xref>).</p><p>Statins are widely used in diabetes management and can reduce cardiovascular events (<xref ref-type="bibr" rid="B2">2</xref>). However, a proportion of statin-treated patients remain at risk of cardiovascular disease. Statins inhibit conversion of 3-hydroxy-3-methylglutaryl-CoA to mevalonate, but may thereby also decrease production of other intermediates in the cholesterol biosynthetic pathway, such as coenzyme Q<sub>10</sub> (CoQ<sub>10</sub>) (<xref ref-type="bibr" rid="B3">3</xref>), an important intracellular antioxidant. We hypothesized that oral CoQ<sub>10</sub> supplementation would improve endothelial dysfunction in statin-treated type 2 diabetic patients.</p><sec><title>RESEARCH DESIGN AND METHODS</title><p>We recruited type 2 diabetic patients aged 40&#x02013;79 years on stable-dose statin therapy for &#x02265;6 weeks. Inclusion criteria were serum LDL cholesterol &#x0003c;2.5 mmol/l and endothelial dysfunction, defined as brachial artery flow-mediated dilatation (FMD) &#x0003c;5.5%. Exclusions included use of antioxidant supplements or other lipid-regulating medications, GHb &#x0003e;8.5%, and blood pressure &#x0003e;150/90 mmHg.</p><p>Eligible subjects were assigned in a double-blind and randomized manner to oral CoQ<sub>10</sub> (200 mg/day) (Blackmores, Balgowlah, Australia) or placebo for 12 weeks. After a 4-week washout, participants crossed over to the alternate treatment. Brachial artery ultrasonography was performed, and fasting blood and 24-h urine samples were collected at the start and end of each treatment period. The Royal Perth Hospital Ethics Committee approved the study.</p><p>The brachial artery was imaged using a 12-MHz transducer connected to an Acuson Aspen ultrasound system (Siemens Medical Solutions, Malvern, PA), and FMD was measured as previously described (<xref ref-type="bibr" rid="B4">4</xref>). Endothelium-independent nitrate-mediated dilatation was measured following sublingual administration of glyceryl trinitrate (400 &#x003bc;g). Ultrasound images were analyzed using semiautomated edge-detection software (<xref ref-type="bibr" rid="B5">5</xref>).</p><p>Total cholesterol, triglycerides, and HDL cholesterol were determined by enzymatic methods, and LDL cholesterol was calculated using the Friedewald equation. GHb was measured using high-performance liquid chromatography. Plasma CoQ<sub>10</sub> was measured by reverse-phase high-performance liquid chromatography using electrochemical detection (interassay coefficient of variation 14%). Plasma F<sub>2</sub>-isoprostane and 24-h urinary 20-hydroxyeicosatetraenoic acid levels (markers of systemic oxidative stress) were measured by gas chromatography-mass spectrometry (interassay coefficients of variation 5.6 and 10%, respectively) (<xref ref-type="bibr" rid="B6">6</xref><xref ref-type="bibr" rid="B7"/>&#x02013;<xref ref-type="bibr" rid="B8">8</xref>).</p><p>Data were analyzed using SPSS 15.0 (Chicago, IL) and SAS 9.1 (Cary, NC). Plasma CoQ<sub>10</sub> data (skewed distribution) were logarithmically transformed for parametric analysis. Treatment effects were compared using mixed-effects models. Carryover effects were examined for and excluded.</p></sec><sec sec-type="results"><title>RESULTS</title><p>Participants were typically middle-aged (mean &#x000b1; SD age 68 &#x000b1; 6 years) and overweight (BMI 29 &#x000b1; 4 kg/m<sup>2</sup>), with satisfactory control of glycemia (GHb 6.9 &#x000b1; 0.7%), blood pressure (systolic 123 &#x000b1; 14 mmHg and diastolic 65 &#x000b1; 7), and lipids (LDL cholesterol 1.8 &#x000b1; 0.3 mmol/l). Median duration of diabetes was 8 years. Seventy-eight percent of subjects had a history of hypertension, 48% had a history of stroke or coronary disease, and 26% had microvascular complications. Eighty-three percent of subjects were taking antihyperglycemic medication, most commonly metformin (78%); 52% were taking ACE inhibitors; 21% were taking angiotensin receptor blockers; and 65% were taking aspirin. Atorvastatin was the most commonly prescribed statin (52%), followed by simvastatin (35%) and pravastatin (13%).</p><p>Baseline brachial artery diameter was similar at all assessments and unaltered by CoQ<sub>10</sub> supplementation (<xref ref-type="table" rid="T1">Table 1</xref>). CoQ<sub>10</sub> increased brachial artery FMD by mean &#x000b1; SEM 1.0 &#x000b1; 0.5% (<italic>P</italic> = 0.04) compared with placebo but did not alter nitrate-mediated dilatation (<italic>P</italic> = 0.66). Absolute percent FMD pre- and postplacebo, pre- and post-CoQ<sub>10</sub>, and change in percent FMD with placebo and CoQ<sub>10</sub> are shown in supplemental Figures A1, A2, and A3 (available in an online appendix at <ext-link ext-link-type="uri" xlink:href="http://care.diabetesjournals.org/cgi/content/full/dc08-1736/DC1">http://care.diabetesjournals.org/cgi/content/full/dc08-1736/DC1</ext-link>), re- spectively. Despite increasing plasma CoQ<sub>10</sub> levels 2.7-fold (<italic>P</italic> &#x0003c; 0.001), CoQ<sub>10</sub> supplementation did not alter plasma F<sub>2</sub>-isoprostane (<italic>P</italic> = 0.58) or urinary 20-hydroxyeicosatetraenoic acid levels (<italic>P</italic> = 0.28) or influence glycemia, blood pressure, or lipids (<italic>P</italic> &#x0003e; 0.05).</p><table-wrap id="T1" position="float"><label>Table 1</label><caption><p>Effect of placebo and oral CoQ<sub>10</sub> on arterial function, biochemical variables, and blood pressure</p></caption><table frame="hsides" rules="groups"><thead valign="bottom"><tr><th rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1">Placebo</th><th align="center" rowspan="1" colspan="1">Oral CoQ<sub>10</sub></th><th align="center" rowspan="1" colspan="1"><italic>P</italic></th></tr></thead><tbody valign="top"><tr><td align="left" rowspan="1" colspan="1">Baseline brachial artery diameter (mm)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x02003;Pretreatment</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">3.9 &#x000b1; 0.1</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">3.9 &#x000b1; 0.1</td><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x02003;Treatment end</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">3.9 &#x000b1; 0.1</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">3.9 &#x000b1; 0.1</td><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x02003;Change</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">&#x02212;0.1 &#x000b1; 0.0</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">0.0 &#x000b1; 0.0</td><td align="char" char="." rowspan="1" colspan="1">0.69</td></tr><tr><td align="left" rowspan="1" colspan="1">Brachial artery FMD (%)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x02003;Pretreatment</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">2.2 &#x000b1; 0.6</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">2.2 &#x000b1; 0.7</td><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x02003;Treatment end</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">2.1 &#x000b1; 0.7</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">3.2 &#x000b1; 0.5</td><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x02003;Change</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">0.0 &#x000b1; 0.5</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">1.0 &#x000b1; 0.6</td><td align="char" char="." rowspan="1" colspan="1">0.04</td></tr><tr><td align="left" rowspan="1" colspan="1">Brachial artery NMD (%)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x02003;Pretreatment</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">16.9 &#x000b1; 1.1</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">17.3 &#x000b1; 0.9</td><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x02003;Treatment end</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">17.8 &#x000b1; 1.0</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">17.5 &#x000b1; 1.0</td><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x02003;Change</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">0.9 &#x000b1; 0.9</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">0.2 &#x000b1; 0.8</td><td align="char" char="." rowspan="1" colspan="1">0.66</td></tr><tr><td align="left" rowspan="1" colspan="1">Plasma CoQ<sub>10</sub> (&#x003bc;mol/l)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x02003;Pretreatment</td><td align="char" char="(" rowspan="1" colspan="1">0.9 (0.2)</td><td align="char" char="(" rowspan="1" colspan="1">0.8 (0.3)</td><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x02003;Treatment end</td><td align="char" char="(" rowspan="1" colspan="1">0.8 (0.2)</td><td align="char" char="(" rowspan="1" colspan="1">2.2 (1.5)</td><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x02003;Change</td><td align="char" char="(" rowspan="1" colspan="1">0.0 (0.1)</td><td align="char" char="(" rowspan="1" colspan="1">1.2 (1.5)</td><td align="char" char="." rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">Plasma F<sub>2</sub>-isoprostanes (pmol/l)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x02003;Pretreatment</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">1,302 &#x000b1; 68</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">1,284 &#x000b1; 70</td><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x02003;Treatment end</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">1,275 &#x000b1; 86</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">1,298 &#x000b1; 69</td><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x02003;Change</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">&#x02212;27 &#x000b1; 55</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">14 &#x000b1; 42</td><td align="char" char="." rowspan="1" colspan="1">0.58</td></tr><tr><td align="left" rowspan="1" colspan="1">Urinary 20-HETE (pmol/24 h)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x02003;Pretreatment</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">828 &#x000b1; 102</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">831 &#x000b1; 109</td><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x02003;Treatment end</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">775 &#x000b1; 104</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">888 &#x000b1; 126</td><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x02003;Change</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">&#x02212;53 &#x000b1; 80</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">57 &#x000b1; 117</td><td align="char" char="." rowspan="1" colspan="1">0.28</td></tr><tr><td align="left" rowspan="1" colspan="1">GHb (%)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x02003;Pretreatment</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">7.0 &#x000b1; 0.1</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">7.0 &#x000b1; 0.2</td><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x02003;Treatment end</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">6.9 &#x000b1; 0.2</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">7.0 &#x000b1; 0.2</td><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x02003;Change</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">&#x02212;0.1 &#x000b1; 0.1</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">&#x02212;0.1 &#x000b1; 0.1</td><td align="char" char="." rowspan="1" colspan="1">0.58</td></tr><tr><td align="left" rowspan="1" colspan="1">LDL cholesterol (mmol/l)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x02003;Pretreatment</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">1.9 &#x000b1; 0.1</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">1.7 &#x000b1; 0.1</td><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x02003;Treatment end</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">1.9 &#x000b1; 0.1</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">2.0 &#x000b1; 0.1</td><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x02003;Change</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">0.1 &#x000b1; 0.1</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">0.2 &#x000b1; 0.1</td><td align="char" char="." rowspan="1" colspan="1">0.41</td></tr><tr><td align="left" rowspan="1" colspan="1">Systolic blood pressure (mmHg)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x02003;Pretreatment</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">126 &#x000b1; 4</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">122 &#x000b1; 3</td><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x02003;Treatment end</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">121 &#x000b1; 3</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">121 &#x000b1; 4</td><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x02003;Change</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">&#x02212;4 &#x000b1; 3</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">&#x02212;1 &#x000b1; 2</td><td align="char" char="." rowspan="1" colspan="1">0.38</td></tr><tr><td align="left" rowspan="1" colspan="1">Diastolic blood pressure (mmHg)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x02003;Pretreatment</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">67 &#x000b1; 1</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">64 &#x000b1; 2</td><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x02003;Treatment end</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">65 &#x000b1; 1</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">66 &#x000b1; 1</td><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x02003;Change</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">&#x02212;2 &#x000b1; 1</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">1 &#x000b1; 1</td><td align="char" char="." rowspan="1" colspan="1">0.09</td></tr></tbody></table><table-wrap-foot><fn><p>Data are means &#x000b1; SEM or medians (interquartile range). Treatment effects compared using mixed-effects models, with adjustment for baseline, treatment sequence, and period. 20-HETE, 20-hydroxyeicosatetraenoic acid; NMD, nitrate-mediated dilatation.</p></fn></table-wrap-foot></table-wrap></sec><sec sec-type="conclusions"><title>CONCLUSIONS</title><p>The new finding was that CoQ<sub>10</sub> supplementation improved endothelial dysfunction in statin-treated type 2 diabetic patients, with no alteration in two markers of systemic oxidative stress. This is consistent with our previous study in statin-naive dyslipidemic type 2 diabetic patients in whom oral CoQ<sub>10</sub> also improved brachial artery FMD but did not alter plasma F<sub>2</sub>-isoprostane levels (<xref ref-type="bibr" rid="B4">4</xref>). However, a study in coronary heart disease patients (20% with diabetes and 80% statin-treated) showed that oral CoQ<sub>10</sub> increased both brachial artery FMD and endothelium-bound extracellular superoxide dismutase activity, suggesting that the beneficial effects on endothelial function are related to improvements in local vascular oxidative stress (<xref ref-type="bibr" rid="B9">9</xref>). CoQ<sub>10</sub> could also decrease vascular oxidative stress by recoupling endothelial nitric oxide synthase and/or mitochondrial oxidative phosphorylation. The fact that plasma F<sub>2</sub>-isoprostane levels in our diabetic subjects were not significantly different from those in our previously studied nondiabetic control subjects (1,360 &#x000b1; 74 vs. 1,394 &#x000b1; 122 pmol/l, respectively; <italic>P</italic> = 0.80) (<xref ref-type="bibr" rid="B4">4</xref>) probably reflects their satisfactory glycemic control; our results might have differed had we included patients with greater degrees of hyperglycemia and systemic oxidative stress. Whether CoQ<sub>10</sub> supplementation might improve endothelial function by modulating other vasoactive mediators, such as endothelin 1 (<xref ref-type="bibr" rid="B10">10</xref>) or asymmetric dimethylarginine, (<xref ref-type="bibr" rid="B11">11</xref>) merits further investigation.</p><p>Our statin-treated subjects had lower plasma CoQ<sub>10</sub> concentrations compared with those in the statin-naive dyslipidemic type 2 diabetic patients in our previous study (0.8 [0.2] vs. 1.3 [0.6] &#x003bc;mol/l; <italic>P</italic> &#x0003c; 0.01) (<xref ref-type="bibr" rid="B4">4</xref>). Although the lowering of plasma CoQ<sub>10</sub> concentrations with pravastatin therapy was not shown to predict cardiovascular outcomes in coronary patients (<xref ref-type="bibr" rid="B12">12</xref>), the effect of pravastatin (40 mg/day) on plasma CoQ<sub>10</sub> levels was modest (&#x0223c;15% reduction vs. placebo) and inhibition of endogenous CoQ<sub>10</sub> production may be greater with higher doses of more potent statins (<xref ref-type="bibr" rid="B3">3</xref>).</p><p>The patients in our study had endothelial dysfunction despite satisfactory control of blood pressure, glycemia, and lipids and may be representative of the proportion of statin-treated patients at increased residual risk of cardiovascular disease. Our absolute improvement in FMD of 1% with CoQ<sub>10</sub> supplementation may potentially translate to a 10&#x02013;25% reduction in residual cardiovascular risk in these patients (<xref ref-type="bibr" rid="B13">13</xref>,<xref ref-type="bibr" rid="B14">14</xref>). Impaired FMD is a consistent predictor of adverse cardiovascular events. Several interventions that improve FMD also improve cardiovascular outcomes (<xref ref-type="bibr" rid="B13">13</xref><xref ref-type="bibr" rid="B14"/>&#x02013;<xref ref-type="bibr" rid="B15">15</xref>). The significance of the findings in our report, however, requires further investigation in a clinical end point trial.</p></sec>
<sec sec-type="supplementary-material">
<title>Supplementary Material</title>
<supplementary-material id="PMC_1" content-type="local-data">
<caption>
<title>Online-Only Appendix</title>
</caption>
<media mimetype="text" mime-subtype="html" xlink:href="dc08-1736_index.html"/>
<media xlink:role="associated-file" mimetype="application" mime-subtype="msword" xlink:href="dc08-1736_dc08-1736_Online_appendix.doc"/>
</supplementary-material>
</sec>
</body><back><fn-group><fn fn-type="financial-disclosure"><p>The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked &#x0201c;advertisement&#x0201d; in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.</p></fn></fn-group><ack><title>Acknowledgments</title><p>S.J.H. and G.T.C. were supported by National Health and Medical Research Council Postgraduate Research Scholarships.</p><p>This study was funded by a Cardiovascular Lipid Research Grant from Pfizer (West Ryde, Australia). Blackmores (Balgowlah, Australia) kindly supplied the CoQ<sub>10</sub> and matching placebo capsules. No other potential conflicts of interest relevant to this article were reported.</p><p>Parts of this study were presented in poster form at the annual scientific meeting of the Australian Atherosclerosis Society, Sydney, Australia, 28&#x02013;31 October 2008.</p><p>We thank Lisa Rich for assistance with ultrasonography, Professor Kevin Croft and Adeline Indrawan for assistance with laboratory analyses, and the study participants involved.</p></ack><ref-list><title>References</title><ref id="B1"><label>1</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Chew</surname><given-names>GT</given-names></name><name><surname>Watts</surname><given-names>GF</given-names></name></person-group>:
<article-title>Coenzyme Q<sub>10</sub> and diabetic endotheliopathy: oxidative stress and the &#x02018;recoupling hypothesis&#x02019;</article-title>.
<source>QJM</source><year>2004</year>;
<volume>97</volume>:
<fpage>537</fpage>&#x02013;
<lpage>548</lpage><pub-id pub-id-type="pmid">15256611</pub-id></citation></ref><ref id="B2"><label>2</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Collins</surname><given-names>R</given-names></name><name><surname>Armitage</surname><given-names>J</given-names></name><name><surname>Parish</surname><given-names>S</given-names></name><name><surname>Sleigh</surname><given-names>P</given-names></name><name><surname>Peto</surname><given-names>R</given-names></name></person-group>:;
<collab>Heart Protection Study Collaborative Group</collab>
<article-title>MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial</article-title>.
<source>Lancet</source><year>2003</year>;
<volume>361</volume>:
<fpage>2005</fpage>&#x02013;
<lpage>2016</lpage><pub-id pub-id-type="pmid">12814710</pub-id></citation></ref><ref id="B3"><label>3</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Littarru</surname><given-names>GP</given-names></name><name><surname>Langsjoen</surname><given-names>P</given-names></name></person-group>:
<article-title>Coenzyme Q<sub>10</sub> and statins: biochemical and clinical implications</article-title>.
<source>Mitochondrion</source><year>2007</year>;
<volume>7</volume>(
<issue>Suppl.</issue>):
<fpage>S168</fpage>&#x02013;
<lpage>S174</lpage><pub-id pub-id-type="pmid">17482884</pub-id></citation></ref><ref id="B4"><label>4</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Watts</surname><given-names>GF</given-names></name><name><surname>Playford</surname><given-names>DA</given-names></name><name><surname>Croft</surname><given-names>KD</given-names></name><name><surname>Ward</surname><given-names>NC</given-names></name><name><surname>Mori</surname><given-names>TA</given-names></name><name><surname>Burke</surname><given-names>V</given-names></name></person-group>:
<article-title>Coenzyme Q<sub>10</sub> improves endothelial dysfunction of the brachial artery in Type II diabetes mellitus</article-title>.
<source>Diabetologia</source><year>2002</year>;
<volume>45</volume>:
<fpage>420</fpage>&#x02013;
<lpage>426</lpage><pub-id pub-id-type="pmid">11914748</pub-id></citation></ref><ref id="B5"><label>5</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Woodman</surname><given-names>RJ</given-names></name><name><surname>Playford</surname><given-names>DA</given-names></name><name><surname>Watts</surname><given-names>GF</given-names></name><name><surname>Cheetham</surname><given-names>C</given-names></name><name><surname>Reed</surname><given-names>C</given-names></name><name><surname>Taylor</surname><given-names>RR</given-names></name><name><surname>Puddey</surname><given-names>IB</given-names></name><name><surname>Beilin</surname><given-names>LJ</given-names></name><name><surname>Burke</surname><given-names>V</given-names></name><name><surname>Mori</surname><given-names>TA</given-names></name><name><surname>Green</surname><given-names>D</given-names></name></person-group>:
<article-title>Improved analysis of brachial artery ultrasound using a novel edge-detection software system</article-title>.
<source>J Appl Physiol</source><year>2001</year>;
<volume>91</volume>:
<fpage>929</fpage>&#x02013;
<lpage>937</lpage><pub-id pub-id-type="pmid">11457812</pub-id></citation></ref><ref id="B6"><label>6</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mori</surname><given-names>TA</given-names></name><name><surname>Croft</surname><given-names>KD</given-names></name><name><surname>Puddey</surname><given-names>IB</given-names></name><name><surname>Beilin</surname><given-names>LJ</given-names></name></person-group>:
<article-title>An improved method for the measurement of urinary and plasma F2-isoprostanes using gas chromatography-mass spectrometry</article-title>.
<source>Anal Biochem</source><year>1999</year>;
<volume>268</volume>:
<fpage>117</fpage>&#x02013;
<lpage>125</lpage><pub-id pub-id-type="pmid">10036170</pub-id></citation></ref><ref id="B7"><label>7</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rivera</surname><given-names>J</given-names></name><name><surname>Ward</surname><given-names>N</given-names></name><name><surname>Hodgson</surname><given-names>J</given-names></name><name><surname>Puddey</surname><given-names>IB</given-names></name><name><surname>Falck</surname><given-names>JR</given-names></name><name><surname>Croft</surname><given-names>KD</given-names></name></person-group>:
<article-title>Measurement of 20-hydroxyeicosatetraenoic acid in human urine by gas chromatography-mass spectrometry</article-title>.
<source>Clin Chem</source><year>2004</year>;
<volume>50</volume>:
<fpage>224</fpage>&#x02013;
<lpage>226</lpage><pub-id pub-id-type="pmid">14709657</pub-id></citation></ref><ref id="B8"><label>8</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ward</surname><given-names>NC</given-names></name><name><surname>Puddey</surname><given-names>IB</given-names></name><name><surname>Hodgson</surname><given-names>J</given-names></name><name><surname>Beilin</surname><given-names>LJ</given-names></name><name><surname>Croft</surname><given-names>KD</given-names></name></person-group>:
<article-title>Urinary 20-hydroxyeicosatetraenoic acid excretion is associated with oxidative stress in hypertensive subjects</article-title>.
<source>Free Radic Biol Med</source><year>2005</year>;
<volume>38</volume>:
<fpage>1032</fpage>&#x02013;
<lpage>1036</lpage><pub-id pub-id-type="pmid">15780761</pub-id></citation></ref><ref id="B9"><label>9</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tiano</surname><given-names>L</given-names></name><name><surname>Belardinelli</surname><given-names>R</given-names></name><name><surname>Carnevali</surname><given-names>P</given-names></name><name><surname>Principi</surname><given-names>F</given-names></name><name><surname>Seddaiu</surname><given-names>G</given-names></name><name><surname>Littarru</surname><given-names>GP</given-names></name></person-group>:
<article-title>Effect of coenzyme Q<sub>10</sub> administration on endothelial function and extracellular superoxide dismutase in patients with ischaemic heart disease: a double-blind, randomized controlled study</article-title>.
<source>Eur Heart J</source><year>2007</year>;
<volume>28</volume>:
<fpage>2249</fpage>&#x02013;
<lpage>2255</lpage><pub-id pub-id-type="pmid">17644511</pub-id></citation></ref><ref id="B10"><label>10</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cardillo</surname><given-names>C</given-names></name><name><surname>Campia</surname><given-names>U</given-names></name><name><surname>Bryant</surname><given-names>MB</given-names></name><name><surname>Panza</surname><given-names>JA</given-names></name></person-group>:
<article-title>Increased activity of endogenous endothelin in patients with type II diabetes mellitus</article-title>.
<source>Circulation</source><year>2002</year>;
<volume>106</volume>:
<fpage>1783</fpage>&#x02013;
<lpage>1787</lpage><pub-id pub-id-type="pmid">12356630</pub-id></citation></ref><ref id="B11"><label>11</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Yasuda</surname><given-names>S</given-names></name><name><surname>Miyazaki</surname><given-names>S</given-names></name><name><surname>Kanda</surname><given-names>M</given-names></name><name><surname>Goto</surname><given-names>Y</given-names></name><name><surname>Suzuki</surname><given-names>M</given-names></name><name><surname>Harano</surname><given-names>Y</given-names></name><name><surname>Nonogi</surname><given-names>H</given-names></name></person-group>:
<article-title>Intensive treatment of risk factors in patients with type-2 diabetes mellitus is associated with improvement of endothelial function coupled with a reduction in the levels of plasma asymmetric dimethylarginine and endogenous inhibitor of nitric oxide synthase</article-title>.
<source>Eur Heart J</source><year>2006</year>;
<volume>27</volume>:
<fpage>1159</fpage>&#x02013;
<lpage>1165</lpage><pub-id pub-id-type="pmid">16627554</pub-id></citation></ref><ref id="B12"><label>12</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Stocker</surname><given-names>R</given-names></name><name><surname>Pollicino</surname><given-names>C</given-names></name><name><surname>Gay</surname><given-names>CA</given-names></name><name><surname>Nestel</surname><given-names>P</given-names></name><name><surname>Colquhoun</surname><given-names>D</given-names></name><name><surname>Whiting</surname><given-names>M</given-names></name><name><surname>Tonkin</surname><given-names>A</given-names></name><name><surname>Sullivan</surname><given-names>D</given-names></name><name><surname>Simes</surname><given-names>J</given-names></name></person-group>:
<article-title>Neither plasma coenzyme Q<sub>10</sub> concentration, nor its decline during pravastatin therapy, is linked to recurrent cardiovascular disease events: a prospective case-control study from the LIPID study</article-title>.
<source>Atherosclerosis</source><year>2006</year>;
<volume>187</volume>:
<fpage>198</fpage>&#x02013;
<lpage>204</lpage><pub-id pub-id-type="pmid">16219312</pub-id></citation></ref><ref id="B13"><label>13</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Neunteufl</surname><given-names>T</given-names></name><name><surname>Heher</surname><given-names>S</given-names></name><name><surname>Katzenschlager</surname><given-names>R</given-names></name><name><surname>Wolfl</surname><given-names>G</given-names></name><name><surname>Kostner</surname><given-names>K</given-names></name><name><surname>Maurer</surname><given-names>G</given-names></name><name><surname>Weidinger</surname><given-names>F</given-names></name></person-group>:
<article-title>Late prognostic value of flow-mediated dilation in the brachial artery of patients with chest pain</article-title>.
<source>Am J Cardiol</source><year>2000</year>;
<volume>86</volume>:
<fpage>207</fpage>&#x02013;
<lpage>210</lpage><pub-id pub-id-type="pmid">10913483</pub-id></citation></ref><ref id="B14"><label>14</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Shimbo</surname><given-names>D</given-names></name><name><surname>Grahame-Clarke</surname><given-names>C</given-names></name><name><surname>Miyake</surname><given-names>Y</given-names></name><name><surname>Rodriguez</surname><given-names>C</given-names></name><name><surname>Sciacca</surname><given-names>R</given-names></name><name><surname>Di Tullio</surname><given-names>M</given-names></name><name><surname>Boden-Albala</surname><given-names>B</given-names></name><name><surname>Sacco</surname><given-names>R</given-names></name><name><surname>Homma</surname><given-names>S</given-names></name></person-group>:
<article-title>The association between endothelial dysfunction and cardiovascular outcomes in a population-based multi-ethnic cohort</article-title>.
<source>Atherosclerosis</source><year>2007</year>;
<volume>192</volume>:
<fpage>197</fpage>&#x02013;
<lpage>203</lpage><pub-id pub-id-type="pmid">16762358</pub-id></citation></ref><ref id="B15"><label>15</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Widlansky</surname><given-names>ME</given-names></name><name><surname>Gokce</surname><given-names>N</given-names></name><name><surname>Keaney</surname><given-names>JF</given-names></name><name><surname>Vita</surname><given-names>JA</given-names></name></person-group>:
<article-title>The clinical implications of endothelial dysfunction</article-title>.
<source>J Am Coll Cardiol</source><year>2003</year>;
<volume>42</volume>:
<fpage>1149</fpage>&#x02013;
<lpage>1160</lpage><pub-id pub-id-type="pmid">14522472</pub-id></citation></ref></ref-list></back></article>





